How has AstraZeneca's R&D spending trended over the past three years?

AstraZeneca's Research and Development (R&D) spending has demonstrated a consistent upward trajectory over the past three years, with the expenditure figures for 2024, 2023, and 2022 reporting $4.68 billion, $3.07 billion, and $2.63 billion, respectively. This indicates a progressive increase in the company's investment in R&D activities, which is a positive signal for future innovation and product pipeline growth.

|code|Ticker|Name|Date|R&D Expenses|R&D Expenses YoY|market_code|
|---|---|---|---|---|---|---|
|AZN|AZN.O|Astrazeneca|2022 Q1|2.133E9|24.518388791593697|185|
|AZN|AZN.O|Astrazeneca|2022 Q2|2.546E9|39.20174958993986|185|
|AZN|AZN.O|Astrazeneca|2022 Q3|2.458E9|-31.91135734072022|185|
|AZN|AZN.O|Astrazeneca|2022 Q4|2.625E9|1.5866873065015479|185|
|AZN|AZN.O|Astrazeneca|2023 Q1|2.611E9|22.409751523675574|185|
|AZN|AZN.O|Astrazeneca|2023 Q2|2.667E9|4.752553024351924|185|
|AZN|AZN.O|Astrazeneca|2023 Q3|2.584E9|5.126118795768917|185|
|AZN|AZN.O|Astrazeneca|2023 Q4|3.073E9|17.066666666666666|185|
|AZN|AZN.O|Astrazeneca|2024 Q1|2.783E9|6.58751436231329|185|
|AZN|AZN.O|Astrazeneca|2024 Q2|3.008E9|12.785901762279714|185|